Exacerbated central fatigue and reduced exercise capacity in early-stage breast cancer patients treated with chemotherapy.
Central and peripheral fatigue
Critical force
Exercise tolerance
Neuromuscular fatigue
Neuromuscular function
Journal
European journal of applied physiology
ISSN: 1439-6327
Titre abrégé: Eur J Appl Physiol
Pays: Germany
ID NLM: 100954790
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
06
10
2022
accepted:
07
03
2023
medline:
19
6
2023
pubmed:
21
3
2023
entrez:
20
3
2023
Statut:
ppublish
Résumé
The present study aimed to characterize the etiology of exercise-induced neuromuscular fatigue and its consequences on the force-duration relationship to provide mechanistic insights into the reduced exercise capacity characterizing early-stage breast cancer patients. Fifteen early-stage breast cancer patients and fifteen healthy women performed 60 maximal voluntary isometric quadriceps contractions (MVCs, 3 s of contraction, 2 s of relaxation). The critical force was determined as the mean force of the last six contractions, while W' was calculated as the force impulse generated above the critical force. Quadriceps muscle activation during exercise was estimated from vastus lateralis, vastus medialis and rectus femoris EMG. Central and peripheral fatigue were quantified via changes in pre- to postexercise quadriceps voluntary activation (ΔVA) and quadriceps twitch force (ΔQTw) evoked by supramaximal electrical stimulation, respectively. Early-stage breast cancer patients demonstrated lower MVC than controls preexercise (- 15%, P = 0.022), and this reduction persisted throughout the 60-MVC exercise (- 21%, P = 0.002). The absolute critical force was lower in patients than in controls (144 ± 29N vs. 201 ± 47N, respectively, P < 0.001), while W' was similar (P = 0.546), resulting in lower total work done (- 23%, P = 0.001). This was associated with lower muscle activation in the vastus lateralis (P < 0.001), vastus medialis (P = 0.003) and rectus femoris (P = 0.003) in patients. Immediately following exercise, ΔVA showed a greater reduction in patients compared to controls (- 21.6 ± 13.3% vs. - 12.6 ± 7.7%, P = 0.040), while ΔQTw was similar (- 60.2 ± 13.2% vs. - 52.8 ± 19.4%, P = 0.196). These findings support central fatigue as a primary cause of the reduction in exercise capacity characterizing early-stage breast cancer patients treated with chemotherapy. No. NCT04639609-November 20, 2020.
Identifiants
pubmed: 36939876
doi: 10.1007/s00421-023-05177-5
pii: 10.1007/s00421-023-05177-5
pmc: PMC10276104
doi:
Banques de données
ClinicalTrials.gov
['NCT04639609']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1567-1581Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2014 Dec 22;9(12):e115370
pubmed: 25532032
J Clin Oncol. 2000 Feb;18(4):743-53
pubmed: 10673515
Am J Physiol Cell Physiol. 2022 Oct 01;323(4):C1325-C1332
pubmed: 36094434
Int J Cardiol. 2014 Jun 15;174(2):368-75
pubmed: 24794967
Ann Oncol. 2014 May;25(5):947-58
pubmed: 24401927
Neuroscience. 2013 Feb 12;231:384-99
pubmed: 23131709
Cancer. 2005 Oct 15;104(8):1772-8
pubmed: 16116608
J Physiol. 2011 Jul 15;589(Pt 14):3533-44
pubmed: 21606110
Eur J Cancer. 2019 Jul;116:98-106
pubmed: 31185387
J Psychosom Res. 2013 Jan;74(1):64-8
pubmed: 23272990
J Appl Physiol (1985). 2009 Jul;107(1):112-20
pubmed: 19443741
Support Care Cancer. 2013 Mar;21(3):873-81
pubmed: 23052910
J Physiol. 2008 Jan 1;586(1):11-23
pubmed: 17702815
J Electromyogr Kinesiol. 2014 Apr;24(2):214-20
pubmed: 24485560
Support Care Cancer. 2017 Apr;25(4):1271-1278
pubmed: 27995318
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Clin Breast Cancer. 2021 Oct;21(5):425-432
pubmed: 33422432
Cancer. 2023 Jan 15;129(2):215-225
pubmed: 36397290
J Natl Cancer Inst Monogr. 2004;(32):93-7
pubmed: 15263047
PLoS One. 2013 Dec 31;8(12):e83636
pubmed: 24391800
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1896-1907
pubmed: 35373507
Clin Sci Mol Med. 1978 Jun;54(6):609-14
pubmed: 657729
Am J Respir Crit Care Med. 2012 Oct 1;186(7):606-15
pubmed: 22822019
J Electromyogr Kinesiol. 2000 Oct;10(5):361-74
pubmed: 11018445
J Appl Physiol (1985). 2002 Apr;92(4):1487-93
pubmed: 11896014
Biol Res Nurs. 2009 Apr;10(4):381-91
pubmed: 19114410
J Physiol. 1954 Mar 29;123(3):553-64
pubmed: 13152698
J Pain Symptom Manage. 2009 Oct;38(4):587-96
pubmed: 19515528
Med Sci Sports Exerc. 2016 Nov;48(11):2320-2334
pubmed: 27031742
J Neurosci Methods. 2020 Dec 1;346:108950
pubmed: 32971133
Ecancermedicalscience. 2020 Jan 27;14:1007
pubmed: 32104209
Acta Oncol. 2019 Sep;58(9):1286-1297
pubmed: 31204538
J Pain Symptom Manage. 2015 Feb;49(2):173-82
pubmed: 25150812
J Neurophysiol. 2008 Feb;99(2):554-63
pubmed: 18046002
J Appl Physiol (1985). 2009 Mar;106(3):975-83
pubmed: 19150854
J Appl Physiol (1985). 2019 Mar 1;126(3):513-543
pubmed: 30496711
J Physiol. 2016 Sep 15;594(18):5303-15
pubmed: 27241818
Breast Cancer Res Treat. 2018 May;169(1):93-103
pubmed: 29349712
J Physiol. 2011 May 15;589(Pt 10):2443-5
pubmed: 21572143
Eur J Clin Nutr. 2013 Jan;67 Suppl 1:S14-21
pubmed: 23299866
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Nat Rev Dis Primers. 2018 Jan 18;4:17105
pubmed: 29345251
J Appl Physiol (1985). 2006 Jun;100(6):1757-64
pubmed: 16424071
Support Care Cancer. 2019 Jan;27(1):229-238
pubmed: 29936623
J Cancer Surviv. 2022 Dec;16(6):1339-1354
pubmed: 34609702
J Pain Symptom Manage. 2012 Sep;44(3):351-61
pubmed: 22835480
Am J Physiol Cell Physiol. 2018 Nov 1;315(5):C744-C756
pubmed: 30207784
J Appl Physiol (1985). 2004 Apr;96(4):1486-95
pubmed: 15016793
J Physiol. 1996 Jan 15;490 ( Pt 2):529-36
pubmed: 8821149
Oncol Nurs Forum. 2008 Sep;35(5):815-21
pubmed: 18765328
Med Sci Sports Exerc. 2022 Aug 1;54(8):1355-1363
pubmed: 35394468
J Clin Oncol. 2012 May 20;30(15):1805-12
pubmed: 22508807
Eur J Sport Sci. 2018 Feb;18(1):13-24
pubmed: 27821022
J Physiol. 2022 Jul;600(13):3069-3081
pubmed: 35593645
Rev Bras Ginecol Obstet. 2014 Jun;36(6):244-50
pubmed: 25099463
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):305-316
pubmed: 27896952
Physiol Rev. 2001 Oct;81(4):1725-89
pubmed: 11581501
Cancer. 2001 Sep 15;92(6 Suppl):1699-707
pubmed: 11598890
Prog Brain Res. 2018;240:219-246
pubmed: 30390833
Eur J Appl Physiol. 2020 Jun;120(6):1289-1304
pubmed: 32253505
Am J Physiol Regul Integr Comp Physiol. 2020 Dec 1;319(6):R617-R625
pubmed: 32966120